Markets & Regulations

© GettyImages/niphon

Moderna to develop mRNA therapeutic for very rare disease

By Jane Byrne

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

© GettyImages/peepo

EU and AstraZeneca reach settlement over vaccine delivery

By Jane Byrne

The European Commission and AstraZeneca have settled their dispute over the supply of COVID-19 vaccine, Vaxzevria, in a move that will see the EU receive 200 million doses of the drug maker’s shot by March 2022.

© GettyImages/Zarina Lukash

Special Edition: Reviewing the advanced therapy pipeline

Santen looks to ways to reduce hurdles for patients in accessing advanced therapies

By Jane Byrne

As a relatively new player in the field of cell therapy, Santen Pharmaceutical has outlined how it is looking to collaborate with key stakeholders in order to shape relevant policies, forge meaningful partnerships and create an optimal environment for...

Follow us

Products

View more

Webinars